

RELATION OF URIC ACID AND HYPERTENSION IN CHRONIC KIDNEY DISEASE AND DIALYSIS PATIENTS

Thesis

Submitted for Partial Fulfillment of Master Degree
of Nephrology

BY

Magdy Morsy Ibrahim

M.B.B.CH

Supervised By

Prof.Dr\Magdy Mohamed El Sherkawy

*Professor of Internal Medicine and Nephrology
Faculty of Medicine - Ain Shams University*

Dr\ Osama Mahmoud Mohamed

*Assistant Professor of Internal Medicine and Nephrology
Faculty of Medicine - Ain Shams University*

Dr\Yasser Mahmoud El Shahawi

*Lecturer In Internal Medicine
Faculty of Medicine - Ain Shams University*

Faculty of Medicine - Ain Shams
University

٢٠١٢



Acknowledgment

First and foremost, I feel always in debted to **ALLAH** the most Merciful the most Gracious. Thanks to Allah who has lightened my path to become a humbled student to a noble profession and granted me the ability to accomplish this work.

I would like to express my sincere thanks and deep appreciation to **Prof. Dr. Magdy Mohamed El Sherkawy** Professor of Internal Medicine and Nephrology; for his support and interest. My deep feeling of gratitude goes to him for close supervision, constructive guidance and meticulous revision of the thesis.

I am profoundly grateful to **Dr. Osama Mahmoud Mohamed**, Assistant Professor of Internal Medicine and Nephrology, for his guidance, valuable comments and careful supervision.

I am forever grateful to all **Dr. Yasser Mahmoud El Shahawi** Lecturer of Internal Medicine, for his constant support, advice, and encouragement throughout my work.

Magdy Morsy Ibrahim

List of Contents

Title	Page No.
Introduction	۱
Aim of the Work	۴
Review of Literature	
Uric Acid.....	۵
Physiology of uric acid and uric acid metabolism.....	۵
Sources of uric acid	۶
Normal ratio of serum uric acid.....	۷
Systemic effect of high uric acid	۸
The antioxidant action of uric acid	۱۰
The renal excretion of uric acid and its regulation	۱۱
Renal failure and serum uric acid level	۱۳
Role of uric acid in cardiovascular morbidity	۱۴
Hypertension and Hyperuricemia	۱۸
Hypertension	۲۱
Signs and symptoms	۲۴
▪ Accelerated hypertension	۲۴
▪ Secondary hypertension.....	۲۴
▪ In pregnancy	۲۵
▪ In children.....	۲۶
Causes of hypertension.....	۲۶
▪ Essential hypertension	۲۶
▪ Secondary hypertension.....	۲۷
Pathophysiology of essential hypertension	۲۸
Diagnosis	۳۵
Prevention.....	۳۷
Complications.....	۳۹

List of Contents (cont...)

Title	Page No.
Chronic Kidney Disease and Hypertension	٤١
Relationship of hypertension to stages of CKD	٤٢
Hypertension as a risk factor for CKD progression	٤٣
Causes of hypertension in CKD	٤٦
Patients and Methods	٤٧
Results.....	٥٠
Discussion	٦٧
Summary and Conclusion.....	٧٤
Recommendation	٧٨
References	٧٩
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (١):	Classification of blood pressure levels of the British Hypertension Society (٢٠٠٧).....	٢٢
Table (٢):	Typical tests needed for diagnose of hypertension	٣٦
Table (٣):	Stages of CKD	٤٢
Table (٤):	Risk factors for CKD and its outcomes.	٤٤
Table (٥):	Shows comparison between group A and group B as regard ECG findings.	٥٠
Table (٦):	Shows comparison between group A and group B using Chi-Square Test.....	٥٢
Table (٧):	Shows comparison between group A and group B as regard clinical and laboratory parameters.	٥٣

List of Figures

Fig. No.	Title	Page No.
Fig. (١):	Shows distribution of ECG findings among group A patients.	٥١
Fig. (٢):	Shows distribution of ECG findings among group B patients.	٥١
Fig. (٣):	Shows comparison between group A and group B as regard systolic B.P.	٥٤
Fig. (٤):	Shows comparison between group A and group B as regard diastolic B.P.	٥٥
Fig. (٥):	Shows comparison between group A and group B as regard hemoglobin level.	٥٥
Fig. (٦):	Shows comparison between group A and group B as regard serum uric acid.	٥٦
Fig. (٧):	Shows comparison between group A and group B as regard serum creatinine.	٥٦
Fig. (٨):	Shows comparison between group A and group B as regard blood urea.	٥٧
Fig. (٩):	Shows comparison between group A and group B as regard B.M.I.	٥٧
Fig. (١٠):	Shows comparison between group A and group B as regard height.	٥٨
Fig. (١١):	Shows comparison between group A and group B as regard weight.	٥٨
Fig. (١٢):	Shows comparison between group A and group B as regard age.	٥٩
Fig. (١٣):	Shows correlation between serum uric acid and systolic B.P.	٥٩
Fig. (١٤):	Shows correlation between serum uric acid and diastolic B.P.	٦٠
Fig. (١٥):	Shows correlation between serum uric acid and G.F.R.	٦٠

List of Figures (cont...)

Fig. No.	Title	Page No.
Fig. (١٦):	Shows correlation between G.F.R and systolic B.P.	٦١
Fig. (١٧):	Shows correlation between G.F.R and diastolic B.P.	٦٢
Fig. (١٨):	Shows correlation between G.F.R and hemoglobin level.	٦٢
Fig. (١٩):	Shows correlation between G.F.R and age.....	٦٣
Fig. (٢٠):	Shows correlation between serum uric acid and systolic blood pressure in group A.	٦٣
Fig. (٢١):	Shows correlation between serum uric acid and diastolic blood pressure in group A.....	٦٤
Fig. (٢٢):	Shows correlation between serum uric acid and hemoglobin level in group A.....	٦٤
Fig. (٢٣):	Shows correlation between serum uric acid and G.F.R in group A.	٦٥
Fig. (٢٤):	Shows correlation between serum uric acid and systolic blood pressure in group B.	٦٥
Fig. (٢٥):	Shows correlation between serum uric acid and diastolic blood pressure in group B.	٦٦
Fig. (٢٦):	Shows correlation between serum uric acid and hemoglobin level in group B.	٦٦
Fig. (٢٧):	Low eGFR prevalence in Italy	٧٢

List of Abbreviations

Abb.	Full term
<i>ACEIs</i>	<i>Angiotensin- converting enzyme inhibitor.</i>
<i>ATP</i>	<i>Adenosine triphosphat .</i>
<i>B.M.I</i>	<i>Body mass index</i>
<i>BP</i>	<i>blood pressure.</i>
<i>BUN</i>	<i>Blood urea nitrogen.</i>
<i>CKD</i>	<i>Chronic kidney disease.</i>
<i>CO</i>	<i>Cardiac output.</i>
<i>CV</i>	<i>Cardiovascular.</i>
<i>D.B.P</i>	<i>Diastolic blood pressure.</i>
<i>DASH diet</i>	<i>Dietary approaches to stop hypertension.</i>
<i>ECV</i>	<i>Extracellular volume.</i>
<i>EET</i>	<i>Epoxyeicosatrienoic acid.</i>
<i>EKG/ECG</i>	<i>Electrocardiogram.</i>
<i>eNO</i>	<i>Endothelial nitric oxide.</i>
<i>eNOS</i>	<i>Endothelial nitric oxide synthase .</i>
<i>ESRD</i>	<i>End-stage renal disease.</i>
<i>ET-1</i>	<i>Endothelin.</i>
<i>GFR</i>	<i>Glomerular filtration rate.</i>
<i>GI</i>	<i>Glycemic index.</i>
<i>H.S</i>	<i>Highly significant.</i>
<i>Hb%</i>	<i>Hemoglobin level.</i>
<i>HD</i>	<i>Hemodialysis.</i>
<i>HDL</i>	<i>High density lipoprotein</i>
<i>HTN</i>	<i>Hypertension.</i>
<i>JNC V</i>	<i>Joint national commete</i>
<i>K/DOQI</i>	<i>Kidney disease outcomes quality initiative.</i>
<i>LDL</i>	<i>Low density lipoprotein</i>
<i>LVH</i>	<i>Left Ventricular hypertrophy.</i>

<i>LVMl</i>	<i>Left Ventricular Mass Index.</i>
<i>MAP</i>	<i>Mean arterial pressure.</i>
<i>N.s</i>	<i>Non-significant.</i>
<i>NAD+</i>	<i>Nicotinamid adenine dinucleotide.</i>
<i>NKF</i>	<i>National kidney foundation.</i>
<i>NOS</i>	<i>Nitric oxide synthase.</i>
<i>PGC</i>	<i>Intra-glomerular pressure.</i>
<i>PTH</i>	<i>parathyroid hormone</i>
<i>QA</i>	<i>Single nephron blood flow.</i>
<i>RA</i>	<i>Afferent arteriolar resistance.</i>
<i>RAS</i>	<i>Renin-angiotensin- system.</i>
<i>RE</i>	<i>Efferent arteriolar resistance.</i>
<i>RF</i>	<i>Renal failure.</i>
<i>ROS</i>	<i>Reactive oxygen species.</i>
<i>RRT</i>	<i>Renal replacement therapy.</i>
<i>S.B.P</i>	<i>Systolic blood pressure.</i>
<i>S.D</i>	<i>Standard deviation.</i>
<i>SNGFR</i>	<i>Single-nephron GFR.</i>
<i>SUA</i>	<i>Serum uric acid.</i>
Thai	Thailand
<i>TSH</i>	<i>Thyroid stimulation hormone</i>
<i>VR</i>	<i>Venous return.</i>
<i>XO</i>	<i>xanthine oxidase.</i>



INTRODUCTION

Many years ago, Sir Alfred Garrod in the 1840s provided the first evidence that gout was associated with increased levels of uric acid in the blood (**Garrod, 1848**).

Shortly thereafter, Frederick Akbar Mohamed first described essential hypertension, and noted that it was often associated with gout. Writing in the *Lancet*, he said: “People who are subject to this high blood pressure frequently belong to gouty families or have themselves suffered from the symptoms of the disease (**Mohamed, 1879**).

After that, many papers reported on the association of gout with hypertension, obesity, and cardiovascular disease. Indeed, in the days before effective therapy was available to lower serum uric acid, more than 70% of patients with gout were obese, more than 80% had hypertension, nearly all had some degree of renal disease (and 10% to 20% died of it) and approximately 90% developed some degree of heart disease (and 20% died of a cardiac complication) (**Breckenridge, 1966**).

Thus, gout seemed to be a major risk factor for cardiovascular disease. And clinically evident gout is only the tip of the iceberg. Many patients have hyperuricemia (uric acid > 7.0 mg/dL in men and > 6.0 mg/dL in women) but do not have gout. Studies in people with “asymptomatic

hyperuricemia” have also demonstrated a remarkable association with hypertension, obesity, metabolic syndrome, kidney disease, and cardiovascular disease (**Johnson et al., 2005**).

Several epidemiologic studies have tried to determine if uric acid is an independent risk factor for cardiovascular disease, some found that it was, but others did not. The inability to resolve these issues, coupled with the lack of a mechanism by which uric acid might cause cardiovascular disease, has up to now led most authorities to conclude that uric acid is not a true risk factor for cardiovascular disease (**Culleton et al., 1999**).

In other studies in rats, experimental hyperuricemia (induced by oxonic acid) was also associated with the development of mild renal disease, characterized by mild proteinuria, renal arteriolar changes, glomerular hypertrophy, tubulointerstitial fibrosis, and eventually glomerulosclerosis (**Nakagawa et al., 2003**).

Interestingly, when hyperuricemia was induced in rats with preexisting renal disease (ie, in which one entire kidney and two thirds of the other kidney had been removed), their renal lesions were dramatically worse than in similar rats without hyperuricemia. This suggests that the hyperuricemia may not only cause renal disease, but may also exacerbate preexistent renal disease (**Kang et al., 2002**).

The mechanism by which uric acid might cause renal disease was revealed by micropuncture studies, which demonstrated that elevated uric acid (3.1 ± 0.2 mg/dL) caused glomerular hypertension and cortical vasoconstriction. These changes would be expected to induce glomerular damage and tubular ischemia. In addition, uric acid stimulated inflammatory mediators in vascular cells, including C-reactive protein and monocyte chemoattractant protein and vasoconstrictive factors such as thromboxane (**Sanchez-Lozada et al., 2002**).

Recent studies in humans also suggest that uric acid is a true risk factor for kidney disease. Numerous recent papers have reported elevated uric acid is an independent risk factor for kidney disease in the general population¹ and in patients with preexistent renal disease (**Toprak et al., 2006**).

Elevated uric acid has also been reported to be more common in patients with diabetes with progressive renal disease. While earlier studies have reported mixed results from lowering uric acid in patients with renal disease. A recent clinical study found that lowering uric acid in patients with renal disease and asymptomatic hyperuricemia resulted in less progression of their renal disease (**Siu et al., 2006**).

AIM OF THE WORK

To study incidence of hyperuricemia in patients with chronic kidney disease and dialysis patients and its relation to hypertension.

Chapter (١):

URIC ACID

Physiology of uric acid and uric acid metabolism

Hyperuricemia can be the consequence of increased uric acid production or decreased excretion. Any cause for decreased glomerular filtration, tubular excretion or increased reabsorption would result in an elevated serum uric acid. Increased serum uric acid has been found to predict the development of renal insufficiency in individuals with normal renal function (**Johnson et al., ٢٠٠٣**).

Uric acid, a product of purine metabolism, is degraded in most mammals by the hepatic enzyme, urate oxidase (uricase), to allantoin, which is freely excreted in the urine (**Richard et al., ٢٠٠٣**).

Uric acid is the final product of purine metabolism in humans. The kidneys excrete approximately two-thirds of the uric acid that is produced daily (**Shihping et al., ٢٠٠٤**).

The serum uric acid concentration is determined largely by the rate of purine metabolism and the efficiency of renal clearance. Therefore, significant amounts of uric acid may accumulate in patients approaching end-stage renal disease (ESRD) (**Shihping et al., ٢٠٠٤**)

Uric acid production has been associated with triglyceride level, and postulated to purine metabolism in triglycerides biosynthesis pathways. Excess purine intake and endogenous production due to glucose intake endure the elevation of uric acid levels (**Kuo Hong et al., ۲۰۰۵**).

Uric acid levels also vary significantly within humans as the result of factors that increase generation (such as high purine or protein diets, alcohol consumption, conditions with high cell turnover, or enzymatic defects in purine metabolism) or decrease excretion (**Baker et al., ۲۰۰۵**).

A reduction in glomerular filtration rate (GFR) increases serum uric acid, although a significant compensatory increase in gastrointestinal excretion occurs (**Richard et al., ۲۰۰۳**).

Sources of uric acid

In many instances, people have elevated uric acid levels for hereditary reasons. Diet may also be a factor. Purines are found in high amounts in animal internal organ food products, such as liver. A moderate amount of purine is also contained in beef, pork, poultry, fish and seafood (**Choi, ۲۰۰۴**).

Examples of high purine sources include: sweetbreads, anchovies, sardines, liver, beef kidneys, brains, herring, mackerel, scallops, game meats, and gravy. Moderate intake of purine-containing food is not associated with an increased risk of gout (**Choi, ۲۰۰۴**).